Other languages MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Market Closed - Nasdaq Other stock markets 02:00:00 27/04/2024 am IST			5-day change	1st Jan Change
3.05 ^USD	-1.61%		-6.15%	-47.41%

11/04	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI
11/04	MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	11/04
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	11/12
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	10/11
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023	07/11
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023	02/11
MEI Pharma, Inc. Announces Board Changes	01/11
MEI Pharma Solicits Proxies from Shareholders	18/23/18
Anson Funds hires Legion Partners' Gupta to build out activism strategy	03/23/03
MEI Pharma Issues Statement Regarding Anson Advisors and Cable Car?s Actions	29/23/29
MEI Pharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	27/23/27
MEI Pharma Reports Institutional Purchase of 32,040 Shares Along With 6,000 Put Options	26/23/26
MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab in Patients with Previously Treated Metastatic Colorectal Cancer	16/23/16
MEI Pharma, Inc. cancelled the acquisition of Infinity Pharmaceuticals, Inc. from The Vanguard Group, Inc. and others.	23/23/23
Anson Funds and Cable Car Capital Respond to MEI Pharma	20/23/20
MEI Pharma Responds to Anson and Cable Car Solicitation	18/23/18
Infinity Pharmaceuticals Shareholders Approve MEI Pharma Merger Deal	14/23/14
MEI Pharma Pushes Back Special Shareholder Meeting to Decide on Pending Infinity Pharmaceuticals Merger	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Other languages

Filters